Table 1.
Patient characteristics and their effects on plasma concentration of AT-all.
| Characteristics | Value N (%) or mean ±SD | Plasma AT-all concentration, ng/mL | |||||
|---|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | ||||||
| mean ±SD | Estimate | p-value | Estimate | p-value | |||
| DEMOGRAPHIC DATA | |||||||
| Total number | 1219 | 9.25 ± 11.19 | |||||
| Age (years) | 62.95 ± 10.00 | 0.0122 | <0.0001 | 0.0140 | <0.0001 | ||
| Sex | Female | 297 (24.36) | 9.89 ± 14.40 | −0.0032 | 0.9633 | ||
| Male | 922 (75.64) | 9.04 ± 9.94 | |||||
| Dosage (mg) | 10 | 21 (1.72) | 4.23 ± 3.69 | 0.0197 | <0.0001 | 0.0173 | <0.0001 |
| 20 | 1058 (86.79) | 8.72 ± 10.47 | |||||
| 40 | 140 (11.48) | 13.98 ± 15.27 | |||||
| SYNTAX score | 13.81 ± 12.19 | 0.0094 | 0.0001 | 0.0059 | 0.0161 | ||
| MEDICAL HISTORY | |||||||
| Arrhythmia | No | 1104 (90.86) | 9.08 ± 10.61 | 0.0707 | 0.4914 | ||
| Yes | 111 (9.14) | 10.98 ± 15.86 | |||||
| Diabetes | No | 895 (73.66) | 8.99 ± 10.56 | 0.0266 | 0.6924 | ||
| Yes | 320 (26.34) | 9.99 ± 12.82 | |||||
| Heart failure | No | 1097 (90.29) | 8.93 ± 10.46 | 0.1210 | 0.2261 | ||
| Yes | 118 (9.71) | 12.24 ± 16.35 | |||||
| Hypertension | No | 499 (41.04) | 8.40 ± 9.14 | 0.0881 | 0.1435 | ||
| Yes | 717 (58.96) | 9.83 ± 12.41 | |||||
| Hyperlipidemia | No | 1073 (88.24) | 9.36 ± 11.28 | −0.0265 | 0.7734 | ||
| Yes | 143 (11.76) | 8.40 ± 10.57 | |||||
| BIOCHEMICAL MEASUREMENTS | |||||||
| ALT, U/L | 28.69 ± 16.80 | 0.0055 | 0.0017 | 0.0059 | 0.0012 | ||
| AST, U/L | 31.05 ± 30.42 | 0.0031 | 0.0014 | ||||
| Scr, μmol/L | 96.70 ± 81.69 | 0.0014 | <0.0001 | 0.0012 | 0.0008 | ||
| eGFR, mL/min/1.73 m2 | 91.26 ± 72.98 | −0.0013 | 0.0013 | ||||
| CK, U/L | 158.91 ± 408.68 | 0.0001 | 0.4328 | ||||
| CKMB, U/L | 8.82 ± 13.67 | 0.0026 | 0.2603 | ||||
| CHOL, mmol/L | 4.32 ± 1.13 | 0.0318 | 0.2305 | ||||
| LDLC, mmol/L | 2.60 ± 0.94 | 0.0569 | 0.0739 | ||||
| HDLC, mmol/L | 0.99 ± 0.26 | −0.1445 | 0.2058 | ||||
| TRIG, mmol/L | 1.58 ± 1.11 | −0.0018 | 0.9463 | ||||
| GLUC, mmol/L | 6.66 ± 2.59 | 0.0267 | 0.0204 | ||||
| Lpa, mg/L | 295.05 ± 315.79 | 0.0003 | 0.0114 | ||||
| APOA, g/L | 1.06 ± 0.29 | −0.3237 | 0.0048 | ||||
| MEDICATION | |||||||
| β-blockers | No | 137 (11.27) | 8.20 ± 8.00 | 0.0263 | 0.7787 | ||
| Yes | 1079 (88.73) | 9.38 ± 11.54 | |||||
| ACEIs | No | 467 (38.4) | 9.46 ± 11.17 | −0.0255 | 0.6761 | ||
| Yes | 749 (61.6) | 9.11 ± 11.22 | |||||
| CCBs | No | 848 (69.74) | 8.93 ± 10.17 | −0.0102 | 0.8743 | ||
| Yes | 368 (30.26) | 9.97 ± 13.25 | |||||
| PPIs | No | 588 (48.36) | 8.69 ± 10.79 | 0.0550 | 0.3535 | ||
| Yes | 628 (51.64) | 9.77 ± 11.55 | |||||
Estimates were calculated by applying a linear regression model.Variables with P < 0.05 were entered into the multivariate model, and only variables with P < 0.05 were retained in the model ACEIs, angiotensin converting enzyme inhibitors; ALT, alanine aminotransferase; APOA, apolipoprotein a; AST, aspartate aminotransferase; CCBs, calcium channel blockers; CHOL, cholesterol; CK, creatine kinase; CKMB, creatine kinase MB; eGFR, estimated glomerular filtration rate; GLUC, glucose; HDLC, high-density lipoprotein cholesterol; LDLC, low-density lipoprotein cholesterol; Lpa, lipoprotein (a); PPIs, proton pump inhibitors; Scr, serum creatinine; SD, standard deviation; SYNTAX score, Synergy between percutaneous coronary intervention with TAXUS and Cardiac Surgery score; TRIG, triglyceride.